Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use JULUCA safely and effectively. See full prescribing information for JULUCA. JULUCA (dolutegravir and rilpivirine tablets), for oral useInitial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA.
- generic_name
- dolutegravir sodium and rilpivirine hydrochloride
- product_names
- dolutegravir sodium and rilpivirine hydrochloride
- ndc
- 49702-242, 49702-242-13
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en